The problem with LOA
Likelihood of Approval (LOA) is a widely referenced metric in drug development, particularly in the later stages of the pipeline.
The problem with PTRS
Probability of Technical and Regulatory Success (PTRS) is a widely used metric in biotech and pharma, employed to estimate the
Assessing the Robustness of Biotech Valuations Using Fat-Tailed Models
Biotech valuations, characterized by their high volatility and dependency on uncertain outcomes, present unique challenges to traditional financial modeling. The
The Project Management Paradox: Why Big Pharma Execs Struggle in the Real World
Project management—the noble art of being handed a budget, a timeline, and a goal, then tasked with delivering results
Why Incorporating Fat Tails, Black Swans, and Extreme Value Theory (EVT) Can Improve Pitch Decks
Fat Tails, Black Swans, and Extreme Value Theory (EVT) offer a robust analytical framework for understanding rare, high-impact events that
WhatsApp: From Skeptic to Believer—How It’s Building Communities
When I first considered WhatsApp as a professional communication channel, I was deeply skeptical. It felt too informal, too personal.
The problem with POL
Probability of Launch (POL) is a comprehensive metric designed to estimate the likelihood that a drug successfully completes all clinical
The problem with DCF
1. Introduction: The Biotech Valuation Maze
Biotech valuation is fraught with complexities that standard financial tools like Discounted Cash Flow
The problem with PRS
Probability of Regulatory Success (PRS) is a metric used to estimate the likelihood that a drug candidate will successfully navigate
On Sitting on the Sidelines: Why Calling Out the Problems Isn’t Enough
Every so often, I wonder if I’m shouting into the void. Not in the performative, social media outrage kind
